Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jan Medical Looks To Sonar For Brain Monitoring Tool

This article was originally published in The Gray Sheet

Executive Summary

After losing his wife to a vasospasm following a hemorrhagic stroke, Paul Lovoi turned to submarine sonar technology to build a company around a device that could diagnose the problem far sooner than can be done today.

You may also be interested in...



News Briefs: FDA Program Alignment Group; CardioMEMS Panel; HCV Coverage Analysis

FDA announces the formation of a new Program Alignment Group, made up of center directors and other officials, and schedules an workshop on intraocular lenses. The agency’s Circulatory System Devices panel will review CardioMEMS’ pulmonary monitoring system again and Medtronic devices. CMS opens coverage analysis for hepatitis C screening. More news.

Research In Brief

Covidien PAD data

Research In Brief

Covidien PAD data

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel